Home › Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin (RX-5902)
 

Keywords :   


Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin (RX-5902)

2013-12-30 06:54:32| drugdiscoveryonline News Articles

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, recently announced that it has been issued United States Patent, No. 8,598,173, which covers a method for treating solid cancer tumors including ovarian, breast, prostate, liver, lung, kidney, colon, pancreatic and stomach for its clinical development candidate Supinoxin (RX-5902)

Tags: method treatment solid patent

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.07Cheap TVs ahead of Euros help slow price inflation
02.07Hurricane Beryl Graphics
02.07Hurricane Beryl Public Advisory Number 14A
02.07Summary for Hurricane Beryl (AT2/AL022024)
02.07Atlantic Tropical Weather Outlook
02.07Eastern North Pacific Tropical Weather Outlook
02.07Murdoch Netflix rival to launch in UK
02.07Hurricane Beryl Forecast Discussion Number 14
More »